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FREDERICK E. WELLER, MA, and ALLAN L. GOLDSTEIN, PhD 
Mitogen-induced suppressor T lymphocyte function was evaluated in patients with 
chronic active hepatitis (CAH). The in vitro effect of the biological response modifier, 
thymosin fraction 5, on the suppressive activity of peripheral blood mononuclear cells 
(PBM) was aiso assessed. Suppressor cell activity was significantly decreased in patients 
with CAH when compared to controls (P < 0.001). In the absence of the inducing mitogen, 
thymosin-treated PBM from both patients and controls promoted enhancement of 
tritiated thymidine uptake by cocultured allogeneic lymphocytes. When thymosin-treated 
mononuclear Cells were mitogen-activated; patients, but not the controls, showed a 
marked increase in suppressor activity (P < 0.001). These results indicate that the 
polypeptides contained in thymosin fraction 5 can promote a helper effect in patients and 
controls. Furthermore, PBM from patients with CAH contain a subset of lymphocytes 
that can express a suppressive function following thymosin treatment. We conclude that 
thymosin fraction 5 can promote an in vitro restoration of suppressor T cell function in 
patients with CAH. 
Chronic active hepatitis (CAH) represents the his- 
tological expression of diverse etiology associated 
with progressive destruction of hepatocytes. An 
immune-mediated disorder may be responsible for 
the perpetuation of hepatic injury observed in some 
patients with CAH (1-7). Abnormalities in immuno- 
regulatory T lymphocytes have been described in a 
variety of immune-associated disorders. These reg- 
ulatory lymphocytes, termed suppressor and helper 
T cells, appear to modulate and regulate both cell- 
Manuscript received February 22, 1982; revised manuscript 
received August 23, 1982; accepted September 6, i982. 
From the Department of Medicine, UniverSity of Michigan 
Medical Center and the Ann Arbor VA Medical Center, Ann 
Arbor, Michigan; the Department of Biochemistry, The George 
Washington University School of Medicine and Health Sciences, 
Washington, DC. 
This study was supported by the Veterans Administration. 
Address for reprint requests: Dr. Milton G. Mutchnick, De- 
partment of Medicine, V.A. Medical Center, 2215 Fuller Road, 
Ann Arbor, Michigan 48105. 
mediated and humoral immune responses (8-10). 
Defects in nonspecifiC suppressor cell function have 
been reported in CAH (11-14), which suggests that 
the normal state of tolerance to hepatocyte autoan- 
tigens may be compromised, resulting in increased 
autoreactive hepatocytotoxic effector cell activity 
(14, 15). 
In previous work we have shown that thymosin 
fraction 5, an extract of calf thymus glands, de- 
creases the in vitro cytotoxic activity of peripheral 
blood mononuclear cells (PBM) obtained from pa- 
tients with CAH (16). Other investigators have 
utilized biologically active thymus-derived factors 
to treat patients with chronic virus-B hepatitis and 
obServed in vivo improvements in T cell counts and 
in immune reactivity (17). 
The thymus gland is critical for the development, 
growth, and function of lymphoid tissue and for the 
maintenance of immune balance (18). The mecha- 
nism by which the thymus exerts its control over T 
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cell development is not clear, but a critical part of 
this control involves the elaboration of  hormones 
which regulate the differentiation of precursor T 
cells and influence the function of  already differen- 
tiated peripheral T cells (19-22). Thymosin fraction 
5 is composed of  at least 16 po!ypeptides with 
differing biologic activities that can act individually, 
sequentially, or in concert  to influence the develop- 
ment of  T cell subpopulations (18). Thymosin has 
also been shown to exert specific effects on regula- 
tory T cell function (18, 23-26). 
Since thymosin fraction 5 contains polypeptides 
which can, at the same time, influence helper or 
suppressor activity, the present studies were under- 
taken to assess thymosin effects on the helper and 
suppressor activity of PBM obtained from patients 
with CAH. 
MATERIALS AND METHODS 
Patients. Eighteen patients had CAH by clinical, bio- 
chemical, and histological criteria (27). The clinical and 
biochemical characteristics of these patients are summa- 
rized in Table 1. There were 12 men and six women with 
an age range of 17-60 years (35.0 --- 3.0, means -- SEM). 
All patients had symptoms and/or biochemical abnormali- 
ties in tests of liver function for at least six months prior 
to biopsy and inclusion in the study. Histologic findings 
included the presence of piecemeal necrosis and bridging 
necrosis in all patients. Four individuals had concomitant 
early cirrhosis. None of the 12 patients lacking hepatitis B 
virus markers in their serum had clinical or morphological 
evidence to suggest alcohol abuse or exposure to known 
hepatotoxic agents. At the time of evaluation four pa- 
tients were taking prednisone and 14 patients were un- 
treated. Five untreated patients were subsequently 
placed on prednisone and evaluated once again one to four 
months after. Eighteen age- (35.4 -- 3.0 years) and sex- 
matched healthy volunteers not known to have current or 
previous liver disease were also studied. Patients and 
controls were excluded if they had malignancy, previous 
known immunodeficiency, a history of recent viral upper 
respiratory illness (28), or were recipients of blood trans- 
fusions within two months of the evaluation. 
Isolation of PBM. Mononuclear cells were isolated from 
the peripheral blood of patients and controls using Ficoll- 
Hypaque gradients as previously described (16). PBM 
were resuspended at 5 • 106 cells/ml in RPMI-1640 
medium (Gibco, Grand Island, New York) enriched with 
vitamins, 2 mM glutamine, penicillin (100 units/ml), strep- 
tomycin (100 ~g/ml), and 10% heat-inactivated fetal calf 
serum (complete medium). Purified bovine thymosin frac- 
tion 5 was prepared (29) and stored at -20 ~ C. Concentra- 
tions ranging from 50 to 400 ~g/ml were used. 
Helper and Suppression Assays. To measure helper and 
suppressor activity promoted by thymosin in the pres- 
ence or absence of concanavalin A ICon A: Pharmacia 
Fine Chemicals. Piscataway, New Jersey), a mixed- 
lymphocyte-culture proliferation assay was used (23, 30) 
with modifications as previously described (31). In the 
initial culture, 0 or 20 Ixg of thymosin in a constant 
volume (0.1 ml) of complete medium was added to 1 ml of 
the PBM SUspension and incubated at 37 ~ C for 24 hr in a 
humidified 5% CO2 and air atmosphere. Parallel tubes 
Containing 1 ml of the PBM suspension plus 0.1 ml of 
complete medium were prepared for immediate use. The 
final volume in each tube was 1.1 ml. Following the 0- or 
24 hr period of incubation, the PBM were resusPended, 
and 0.55 ml of each tube was incubated in the presence or 
absence of Con A (5 Ixg/ml) for an additional 48 hr. These 
constituted the 2-day and 3-day initial cultures, respec- 
tively. After incubation the control and Con A-activated 
cells were treated with 50 Ixg/ml of mitomycin C (Sigma 
Chemical Co., St. Louis, Missouri) for 30 rain, and 
washed twice in 30 mM c~-methylmannoside and once 
again in complete medium. The PBM were resuspended 
at 1 • 10 6 cells/ml in complete medium. 
Fresh PBM (responder cells) from a healthy donor 
were adjusted to 2 • 10 6 cells/ml in complete medium. 
For the coculture experiments, cells from the 2- and 3-day 
initial cultures were incubated with fresh allogeneic re- 
sponder cells from the Same donor for 90 hr. The studies 
were performed in quadruplicate in flat-bottom microtiter 
plates (Costar, Cambridge, Massachusetts) to which were 
added 0.05 ml of responder PBM (1 • 105 cells), 0.1 ml of 
precultured PBM (1 • 105 ceils), and 0.05 ml of complete 
medium containing Con A (40 ixg/ml). In control wells 
0.05 ml of complete medium without Con A were added 
such that the total vOlume in each well was 0.2 ml. 
Tritiated thymidine, 2 ixCi per well (New England Nucle- 
ar, Waltham, Massachusetts), was added 18 hr prior to 
harvesting with an automatic multiple sample harvester 
(Otto Hiller Co., Madison, Wisconsin). The incorporation 
of [3H]thymidine into cells was measured in a Beckman 
liquid scintillation system. 
Effect of Preincubation on Suppressor Activity. Recent 
studies have reported a decrease in Con A-induced Sup- 
pressor activity when PBM in initial culture are incubated 
for 24 hr prior to activation with Con A (32-34). The 
influence of a 24-hr preincubation perio d on suppressor 
activity was determined to assess in vitro loss of suppres- 
sor cell activity (SCA) and to evaluate the suppressor cell 
response to preincubation in the presence of thymosin. 
Calculations of Helper/Suppressor Activity. The sup- 
pression of allogeneic responder ceils by PBM from the 2- 
and 3-day initial cultures not containing thymosin was 
calculated as: % suppression = 1 - (A counts per minute 
(cpm) suppressor cells/A cpm control cells) • 100; where 
/~ cpm = cpm of Con A stimulated cocultures - cpm 
unstimulated cocultures; suppressor = Con A activated 
PBM from initial cultures; control -= PBM not activated 
with Con A in initial cultures. Thymosin effect in the 3- 
day initial cultures was calculated as: % suppression = 1 
- (A cpm thymosin pretreated suppressor cells/A cpm 
thymosin pretreated control cells) • 100. The effect of 
thymosin alone on SCA in the absence of Con A induc- 
tion in the initial cultures was determined as: % suppres- 
sion = 1 - (A cpm thymosin pretreated PBM/A cpm 
untreated PBM) • 100. A positive value indicated sup- 
pression of blast transformation in responder cells, and a 
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TABLE 1. CLINICAL DATA OF 18 PATIENTS WITH CAH 
Liver SGPT l[ y-globulin82 
Patient Age Sex histology* Therapyt HB~Ag/HB~4b/HB~4br ASMA/ANAw (IU/liter) (gm/dl) 
1 17 M CAH O - / - / -  + /+  680 2.4 
2 32 F CAH O - / - / -  - / -  365 3.0 
3 33 M CAH O - / - / -  - / -  200 1.9 
4 24 M CAH O - / - / -  - / +  880 2.1 
5 22 M CAH O - / - / -  - / -  110 1.4 
6 19 F CAH O - / - / -  + / -  640 4.6 
7 26 M CAH-C O - / - / -  - / -  144 2.2 
8 27 F CAH P - / - / -  +/ND 81 2.9 
9 47 M CAH P - / - / -  = /=  65 ND 
10 47 F CAH-C O - / + / -  - / -  23 1.9 
11 54 M CAH O + / - / +  - / -  156 2.3 
12 60 M CAH P + / - +  - / -  405 3.8 
13 47 F CAH P - / - / -  - / -  550 2.1 
14 52 F CAH-C O - / + / +  +/+  302 2.7 
15 32 M CAH O + / - / +  + / -  199 2.0 
16 36 M CAH-C O - / - / -  + / -  1 i2 3.0 
17 30 M CAH O + / - / +  - / -  49 1.6 
18 25 M CAH O + / - / +  - / -  109 2.3 
*CAH, chronic active hepatitis; CAH-C, chronic active hepatitis with cirrhosis. 
tP, prednisone; O, none. 
:~HB~Ag, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBcAb, hepatitis B core antibody; +, positive; - ,  
negative. 
w anti-smooth muscle antibody; ANA, antinuclear antibody; ND, not determined. 
II Serum glutamic-pyruvic transaminase. 
82 'v-globulin. 
negative value reflected enhancement of responder cell 
transformation. Statistical evaluation of SCA in patients 
and controls was accomplished with Student's t test. The 
significance of the modulation in SCA in the presence of 
thymosin was determined using Student's paired t test. 
RESULTS 
Determination of Optimal Thymosin Concentra- 
tion. w e  have previously shown that thymosin does 
not exert a mitogenic effect on PBM and, in healthy 
volunteers, maximum suppression of responder 
cells is observed when PBM in initial cultures are 
incubated with 10 and 20 ~g/ml of thymosin (31). 
Similar results were seen when PBM from six 
patients with CAH were incubated in the absence of 
thymosin (-0.53 • 2.4; % suppression • SEM) or 
with 5 ~g/ml (-21.4 • 11,1), 10 p~g/ml (9.8 • 2.7), 
20 p~g/ml (15.4 • 3.2), and 40 p~g/ml (6.2 • 2.9) of 
thymosin. The effect of thymosin alone on the 
suppressive function of PBM was determined by 
omitting Con A from the initial cultures. A dose- 
response was observed in patients and controls with 
enhancement rather than suppression of [3H]thymi- 
dine incorporation by Con A-stimulated resP0nder 
cells. Maximal enhancement was observed at 10 
and 20 p~g/ml of thymosin. A thymosin concentra- 
tion of 20 ~g/ml was therefore used for the remain- 
ing experiments. 
Con A-Induced Suppression of Mixed-Lympho- 
cyte-Culture Proliferation. The suppression of fresh 
allogeneic responder cells by PBM from the 2-day 
initial cultures !s depicted in Figure 1 and Table 2. A 
significant decrease in  SCA was observed in pa- 
tients with CAH, irrespective of seropositivity for 
the hepatitis B virus. No differences were noted 
between patients with CAH on prednisone treat- 
ment ( -0.5 - 4.6%; mean • SEM) and those not 
receiving medication ( -0 .8  • 3.4%; P = NS). SCA 
in the controls was substantially decreased in the 3- 
day initial cultures not containing thymosin as com- 
pared to the 2-day initial cultures (Table 2). There 
was no corresponding change in the low SCA 
observed in the patient group. 
Thymosin Effect on Suppressor and Helper Activi- 
ty. Thymosin pretreatment of PBM in the 3-day 
initial cultures markedly increased SCA in the pa, 
tient group as compared to parallel untreated cul- 
tures. The responses were the same when CAH 
patients were stratified by seropositivity for tile 
hepatitis B virus or by the presence or absence of 
steroid therapy. Moreover, the suppression pro- 
moted by thymosin in the CAH group was virtually 
identical to that seen in the controls, in whom no 
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F i g  1. Con A-induced suppressor cell activity of peripheral blood 
mononuclear cells in 2-day initial cultures. CAH, total group of 
patients with CAH; CAH B+,  hepatitis B-positive subgroup; 
CAH B-, hepatitis B-negative subgroup. 
significant change in SCA was observed after thy- 
mosin treatment (Table 2). 
The influence of thymosin alone on SCA was 
determined by omitting Con A activation of sup- 
pressor cells in the 3-day initial cultures. Enhance- 
ment rather than suppression of Con A-stimulated 
blast transformation of allogeneic responder cells 
was observed in both the patient and control groups 
(Table 2). 
Influence of Prednisone Treatment on SCA. Five 
patients were examined prior to and from one to 
four months after initiation of prednisone therapy at 
10-20 mg daily. SCA in the 2-day initial cultures 
were not different before and after initiation of 
treatment (2.5 + 4.0%, before; -0 .1  _+ 8.7%, after). 
In a similar manner the response to thymosin did 
not differ before and after initiation of treatment. 
Correlation Between SCA and Biochemical Tests 
of  Liver Function. There were no individual correla- 
tions between the SCA observed in the 2-day initial 
cultures, the suppressor cell response to thymosin 
in the 3-day cultures, the level of enhancement 
promoted by thymosin alone, and biochemical tests 
of liver function including total bilirubin, SGOT, 
SGPT, alkaline phosphatase, and serum gamma 
globulin levels. 
DISCUSSION 
Our previous observation that thymosin fraction 
5 decreased the in vitro cytotoxic activity of PBM 
from patients with CAH suggested that this biologi- 
cal response modifier influenced a subset of lym- 
phocytes that directly mediated cytotoxic activity 
or that exerted immunoregulatory control over the 
actual effector cells (16). The initial report of a 
decrease in Con A-induced SCA in patients with 
CAH (11) prompted the present study to determine 
the effect of thymosin on suppressor T cell function. 
Subsequent investigations have also described al- 
terations in suppressor activity in patients with 
CAH employing assays that monitor T cell suppres- 
sion of pokeweed mitogen-induced immunoglobulin 
TABLE 2. EFFECT OF ~NCUBATION TIME AND THYMOSIN ON SUPPRESSOR CELL ACTIVITY 
Initial cultures 
Duration PBM treated 
Study group (Days) with thymosin 
Con A Suppression (%, 
activation mean q- SEM) P value 
CAH (18)* 2 0 
Controls (18) 2 0 
C A H  (18) 3 0 
Controls (18) 3 0 
CAH (18) 3 + 
Controls (18) 3 + 
CAH (18) 3 + 
Controls (18) 3 + 
+ -0 .9  -+ 2.7 <0.001 
+ 19.8 - 4.3 
+ -1 .3  - 4.0 <0.05 
+ 7.7 +- 1.9t 
+ 12.9 --, 3.15 NS 
+ 11.2 -+ 1.9 
0 -13.8 -+ 2.8 NS 
0 -8 .6  -+ 3.3 
*Numoer of subjects tested given in parenthesis 
t P  < 0.02 compared to 2-day initial cultures of controls, Student's t test. 
$P < 0.001 compared to 3-day initial cultures in the absence of thymosin, Student's paired t test. 
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synthesis (12), mitogen (Con-A) -induced suppres- 
sor T cells (14), short-lived suppressor T cells (13), 
prostaglandin-producing suppressor (monocyte) 
cells (35), and spontaneous suppressor (monocyte) 
cells (14). 
In preliminary work we noted that PBM from 
patients with CAH required a 24-hr incubation with 
thymosin in order to elicit an increase in SCA. This 
requirement for a 24-hr preculture introduced the 
possibility that a loss in short-lived suppressor cells 
might occur in the 3-day initial cultures. These cells 
appear to constitute a distinct group of Con-A 
inducible suppressor cells (33, 34, 36). 
As shown in Table 2, there was a significant 
decrease in SCA in the controls between the 2-day 
and 3-day initial cultures with no appreciable 
change in SCA seen in the patient group. Thus, if 
there were few suppressor cells present in the PBM 
of patients with CAH, a 24-hr preculture period 
would not have influenced the already low suppres- 
sor activity. Conversely the "normal" suppressor 
activity in the controls would decrease with prein- 
cubation. Thymosin did not maintain the functional 
capacity of suppressor cells from the controls, but it 
did increase SCA in patients with CAH. 
It is possible that there are increased numbers of 
precursor suppressor cells (37, 38) in patients with 
CAH, but not in healthy controls, that differentiate 
into suppressor cells in the presence of thymosin 
with subsequent induction by Con A into activated 
cells. This hypothesis is supported by studies re- 
porting a suppression of the proliferative responses 
of human PBM to a variety of mitogens by a 
thymosin-induced suppressor T cell generated from 
a precursor population (39, 40). Furthermore, it is 
not likely that thymosin decreased a helper T cell 
effect in patients with CAH, resulting in an altered 
helper-suppressor balance, as we have shown that 
PBM incubated in the presence of thymosin alone 
promoted enhancement of proliferation in the re- 
sponder cells (Table 2). Moreover, while thymosin 
has been shown to mediate a predominantly helper 
effect in normal human peripheral blood T cells, 
Con A induction can unmask the equivalent sup- 
pressor activity in thymosin-pretreated PBM to that 
observed in PBM from the same individual not 
pretreated with thymosin (31). Alternatively, thy- 
mosin may have corrected intrinsic suppressor cell 
defects in patients with CAH or countered the in 
vivo influence of extrinsic factors such as immune 
complexes and antibodies to suppressor ceils which 
might impair suppressor cell function (41, 42). Con- 
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ceivably, thymosin may have modulated the func- 
tion of a suppressor T cell subset which in turn 
regulates an effector-suppressor T subset (43). 
Although conclusive evidence is lacking, the tar- 
get lymphocyte influenced by thymosin is most 
likely a T cell. This hypothesis is based on the 
following observations. First, thymosin-treated hu- 
man null cells possessing T but not B cell antigens 
will form T cell E rosettes (ER) (44). Furthermore, 
B cell and monocyte numbers or function are not 
directly altered by thymosin (45, 46). Second, in 
vitro studies have shown that thymosin can increase 
both T cell ER and Con A-induced suppressor 
activity in patients with systemic lupus erythemato- 
sus (SLE) (23, 45). Thymosin-induced increases in 
T cell ER, both in vitro and in vivo, have also been 
reported in patients with CAH (17, 47). Third, 
studies in animals indicate that thymosin fraction 5 
can induce in vitro suppressor cells which then 
inhibit the induction of cytotoxic T ceils in a mixed 
lymphocyte-tumor cell culture. These suppressor 
cells have been characterized as Thy 1-positive, 
nonadherent, short-lived T cells (48). 
A variety of immunopathologic disorders are 
associated with perturbations in immunoregulatory 
balance. Thus autoimmunity may result from devi- 
ations in the function of helper or suppressor cells 
(49). Interpretation of the suppressor cell dysfunc- 
tion in CAH as reported in previous studies as well 
as the present study is difficult. All published re- 
ports have underscored the lack of an association 
between suppressor cell function and biochemical 
changes, clinical status, or the presence of steroid 
therapy. This inability to relate suppressor cell 
function in CAH to other parameters of disease 
activity (7) may imply that the described regulatory 
cell changes represent the consequences of, rather 
than the causes for, perpetuation of the disease 
state (50). On the other hand, the lack of a correla- 
tion between SCA and disease indicators may sug- 
gest that the suppressor cell defect in CAH is 
genetically predetermined and is a predisposing 
factor to initiation or perpetuation of the disease. 
Support for this viewpoint has been shown in 
studies where family members of patients with 
SLE, in whom suppressor cell defects are regularly 
found, also have suppressor cell defects in the 
absence of clinical disease (51). 
It is apparent that the relationship between defec- 
tive suppressor cell activity and the pathogenesis of 
CAH requires further examination. The present 
study suggests that the PBM of patients with CAH 
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con ta in  a subse t  of  T l y m p h o c y t e s  which ,  in the 
p re sence  of thymic  h o r m o n e ,  can  express  suppres-  
sor f unc t i on  fol lowing Con  A induc t ion .  This  raises 
the in t r iguing p rospec t  that  there  may  be an alter- 
a t ion  in thymic  regu la t ion  of  T cell d i f ferent ia t ion 
and  func t ion  in pa t ien ts  with C A H .  
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